Patents by Inventor Michael Kastan
Michael Kastan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150772Abstract: Provided herein are compositions including aptamers capable of binding to and/or inhibiting the activity of nucleolin. Methods of treating cancer in a subject by administering such compositions are also provided.Type: ApplicationFiled: June 2, 2023Publication date: May 9, 2024Applicant: Duke UniversityInventors: Bruce A. Sullenger, Michael Goldstein, Elizabeth D. Pratico, Michael Kastan, Bethany Gray
-
Patent number: 11713464Abstract: Provided herein are compositions including aptamers capable of binding to and/or inhibiting the activity of nucleolin. Methods of treating cancer in a subject by administering such compositions are also provided.Type: GrantFiled: September 10, 2018Date of Patent: August 1, 2023Assignee: Duke UniversityInventors: Bruce A. Sullenger, Michael Goldstein, Elizabeth D. Pratico, Michael Kastan, Bethany Gray
-
Publication number: 20220315606Abstract: Provided herein are compounds of the Formula (I), (II), and (III): as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.Type: ApplicationFiled: October 19, 2020Publication date: October 6, 2022Inventors: Jianmin FU, Yaode WANG, Yue SUN, Guosheng WU, Aijun LU, Shuang ZHANG, Robert GOODNOW, Tona GILMER, Michael KASTAN, David KIRSCH
-
Publication number: 20220142995Abstract: Provided herein are compounds of formula (I): and pharmaceutically acceptable salts thereof, where the substituents are as described herein. These compounds and their pharmaceutical compositions may be useful in the treatment of oncologic diseases.Type: ApplicationFiled: January 27, 2022Publication date: May 12, 2022Inventors: Jianmin FU, Yaode WANG, Yue SUN, Guosheng WU, Aijun LU, Shuang ZHANG, Robert A. GOODNOW, Tona GILMER, Michael KASTAN, David KIRSCH
-
Publication number: 20200283773Abstract: Provided herein are compositions including aptamers capable of binding to and/or inhibiting the activity of nucleolin. Methods of treating cancer in a subject by administering such compositions are also provided.Type: ApplicationFiled: September 10, 2018Publication date: September 10, 2020Applicant: Duke UniversityInventors: Bruce A. Sullenger, Michael Goldstein, Elizabeth D. Pratico, Michael Kastan, Bethany Gray
-
Publication number: 20080020462Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.Type: ApplicationFiled: August 17, 2007Publication date: January 24, 2008Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20070009919Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.Type: ApplicationFiled: November 23, 2005Publication date: January 11, 2007Applicant: St. Jude Children's Research HospitalInventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20060241139Abstract: The present invention provides methods and compositions for prophylaxis and treatment of a variety of disorders including DNA damage related disorders, cancer, ischemia, oxidative stress, atherosclerosis, and stroke using a chloroquine compound.Type: ApplicationFiled: June 23, 2006Publication date: October 26, 2006Applicant: St. Jude Children's Research HospitalInventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20050148020Abstract: The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.Type: ApplicationFiled: March 9, 2005Publication date: July 7, 2005Applicant: St. Jude Children's Research HospitalInventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20050124653Abstract: The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment of the invention is a prophylactic method for the prevention of cancer using a chloroquine compound. Another embodiment is a method for the inhibition of side effects associated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds.Type: ApplicationFiled: November 26, 2003Publication date: June 9, 2005Inventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20050032834Abstract: The present invention provides methods and compositions for prophylaxis and treatment of a variety of disorders including DNA damage related disorders, cancer, ischemia, oxidative stress, atherosclerosis, and stroke using a chloroquine compound.Type: ApplicationFiled: May 27, 2004Publication date: February 10, 2005Inventors: Michael Kastan, Christopher Bakkenist
-
Publication number: 20050014785Abstract: The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment is a method for the inhibition of side effects associated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds. Another embodiment is a method for treatment and/or prevention of lethal or sub-lethal radiation toxicities associated with terrorist acts or war.Type: ApplicationFiled: May 27, 2004Publication date: January 20, 2005Applicants: Perlegen Sciences, Inc., St. Jude Children's Research HospitalInventors: Michael Kastan, Christopher Bakkenist, Mark McCamish
-
Publication number: 20030022263Abstract: The present invention relates to identification of the consensus sequence phosphorylated by ATM kinase. This, in turn, permitted identification of ATM kinase target proteins, and development of a convenient assay system for ATM kinase phosphorylation using fusion polypeptides as substrates. The assay system is adaptable to screening for ATM modulators, particularly inhibitors. In a specific embodiment, the substrate recognition sequence and mutagenized variants of this sequence were incorporated in a GST fusion protein and assayed for phosphorylation by ATM kinase. This assay system is useful in screening for ATM inhibitors. ATM function assays were validated using an ATM-kinase dead dominant-negative mutant.Type: ApplicationFiled: December 17, 2001Publication date: January 30, 2003Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Michael Kastan, Christine Canman, Seong-Tae Kim, Dae-Sik Lim
-
Patent number: 6387640Abstract: The present invention relates to identification of the consensus sequence phosphorylated by ATM kinase. This, in turn, permitted identification of ATM kinase target proteins, and development of a convenient assay system for ATM kinase phosphorylation using fusion polypeptides as substrates. The assay system is adaptable to screening for ATM modulators, particularly inhibitors. In a specific embodiment, the substrate recognition sequence and mutagenized variants of this sequence were incorporated in a GST fusion protein and assayed for phosphorylation by ATM kinase. This assay system is useful in screening for ATM inhibitors. ATM function assays were validated using an ATM-kinase dead dominant-negative mutant.Type: GrantFiled: February 10, 1999Date of Patent: May 14, 2002Assignees: St. Jude Children's Research Hospital, Johns-Hopkins UniversityInventors: Michael Kastan, Christine Canman, Seong-Tae Kim, Dae-Sik Lim
-
Patent number: 6348311Abstract: The present invention relates to identification of the consensus sequence phosphorylated by ATM kinase. This, in turn, permitted identification of ATM kinase target proteins, and development of a convenient assay system for ATM kinase phosphorylation using fusion polypeptides as substrates. The assay system is adaptable to screening for ATM modulators, particularly inhibitors. In a specific embodiment, the substrate recognition sequence and mutagenized variants of this sequence were incorporated in a GST fusion protein and assayed for phosphorylation by ATM kinase. This assay system is useful in screening for ATM inhibitors. ATM function assays were validated using an ATM-kinase dead dominant-negative mutant.Type: GrantFiled: September 21, 1999Date of Patent: February 19, 2002Assignees: St. Jude Childre's Research Hospital, Johns-Hopkins UniversityInventors: Michael Kastan, Christine Canman, Seong-Tae Kim, Dae-Sik Lim